USPTO Director Proposes New Patent Eligibility Guidance
Now Available! Seyfarth Shaw’s BioLoquitur Bulletin: Drugs Available in 2018 for Generic Competition
Good ANDA Submission Practices: Summary of Draft Guidance
Innovation in Hatch-Waxman and ANDA Litigation
Now Available! Seyfarth Shaw’s Hatch-Waxman and Biosimilars Litigation: 2017 Year-in-Review
2017 Patent Litigation: A Statistical Overview
FDA Releases Draft Guidance on Determining Whether to Submit an ANDA or a 505(b)(2) Application
Federal Circuit Confirms That It Is Bound By Congress And Supreme Court In Its Standard Of Review Of Appeals Under The AIA
Momenta v. Teva – Effective Claiming of Methods of Testing Drug Products
Subscribe: Subscribe via RSS
Blogs
Firm/Org